227 related articles for article (PubMed ID: 30026184)
1. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding.
Wyseure T; Cooke EJ; Declerck PJ; Behrendt N; Meijers JCM; von Drygalski A; Mosnier LO
Blood; 2018 Oct; 132(15):1593-1603. PubMed ID: 30026184
[TBL] [Abstract][Full Text] [Related]
2. TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.
Wyseure T; Yang T; Zhou JY; Cooke EJ; Wanko B; Olmer M; Agashe R; Morodomi Y; Behrendt N; Lotz M; Morser J; von Drygalski A; Mosnier LO
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31465300
[TBL] [Abstract][Full Text] [Related]
3. Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor.
Foley JH; Nesheim ME
J Thromb Haemost; 2009 Mar; 7(3):453-9. PubMed ID: 19087221
[TBL] [Abstract][Full Text] [Related]
4. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
Soliman M; Osman N; Hefnawy S; El Hawy MA
Pediatr Hematol Oncol; 2022 May; 39(4):318-328. PubMed ID: 34668834
[TBL] [Abstract][Full Text] [Related]
5. Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.
Foley JH; Nesheim ME; Rivard GE; Brummel-Ziedins KE
Haemophilia; 2012 May; 18(3):e316-22. PubMed ID: 21933309
[TBL] [Abstract][Full Text] [Related]
6. Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A.
Semeraro F; Mancuso ME; Ammollo CT; Dirienzo L; Vitulli A; Santagostino E; Tripodi A; Colucci M
J Thromb Haemost; 2020 Feb; 18(2):381-389. PubMed ID: 31571361
[TBL] [Abstract][Full Text] [Related]
7. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
Antovic JP; Schulman S; An SS; Greenfield RS; Blombäck M
Scand J Clin Lab Invest; 2004; 64(8):745-51. PubMed ID: 15719893
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of vascular permeability and remodeling associated with hemarthrosis in factor VIII-deficient mice.
Cooke EJ; Wyseure T; Zhou JY; Gopal S; Nasamran CA; Fisch KM; Manon-Jensen T; Karsdal MA; Mosnier LO; von Drygalski A
J Thromb Haemost; 2019 Nov; 17(11):1815-1826. PubMed ID: 31301687
[TBL] [Abstract][Full Text] [Related]
9. EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.
Magisetty J; Pendurthi UR; Esmon CT; Rao LVM
Blood; 2020 Jun; 135(25):2211-2223. PubMed ID: 32294155
[TBL] [Abstract][Full Text] [Related]
10. On-demand but not prophylactic treatment with FVIII concentrate increase thrombin activatable fibrinolysis inhibitor activation in severe haemophilia A patients.
Mikovic D; Woodhams BJ; Holmström M; Elezovic I; Antovic A; Mobarrez F; Elfvinge P; Antovic JP
Int J Lab Hematol; 2012 Feb; 34(1):35-40. PubMed ID: 21707936
[TBL] [Abstract][Full Text] [Related]
11. Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.
Stagaard R; Flick MJ; Bojko B; Goryński K; Goryńska PZ; Ley CD; Olsen LH; Knudsen T
J Thromb Haemost; 2018 Jul; 16(7):1369-1382. PubMed ID: 29758126
[TBL] [Abstract][Full Text] [Related]
12. The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency.
Vercauteren E; Peeters M; Hoylaerts MF; Lijnen HR; Meijers JC; Declerck PJ; Gils A
J Thromb Haemost; 2012 Dec; 10(12):2555-62. PubMed ID: 23083123
[TBL] [Abstract][Full Text] [Related]
13. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
Mosnier LO
J Biol Chem; 2011 Jan; 286(1):502-10. PubMed ID: 21041299
[TBL] [Abstract][Full Text] [Related]
14. FVIII/VWF complex displays a greater pro-haemostatic activity than FVIII preparations devoid of VWF: Study in plasma and cell-based models.
Ammollo CT; Semeraro F; Vitulli A; Dirienzo L; Mezzasoma AM; Semeraro N; Gresele P; Colucci M
Haemophilia; 2020 Jul; 26(4):e151-e160. PubMed ID: 32325538
[TBL] [Abstract][Full Text] [Related]
15. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.
Nagashima M; Yin ZF; Zhao L; White K; Zhu Y; Lasky N; Halks-Miller M; Broze GJ; Fay WP; Morser J
J Clin Invest; 2002 Jan; 109(1):101-10. PubMed ID: 11781355
[TBL] [Abstract][Full Text] [Related]
16. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.
Wang X; Smith PL; Hsu MY; Tamasi JA; Bird E; Schumacher WA
J Thromb Thrombolysis; 2007 Feb; 23(1):41-9. PubMed ID: 17111204
[TBL] [Abstract][Full Text] [Related]
17. Maladaptive lymphangiogenesis is associated with synovial iron accumulation and delayed clearance in factor VIII-deficient mice after induced hemarthrosis.
Cooke EJ; Joseph BC; Nasamran CA; Fisch KM; von Drygalski A
J Thromb Haemost; 2023 Sep; 21(9):2390-2404. PubMed ID: 37116753
[TBL] [Abstract][Full Text] [Related]
18. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?
Morser J; Gabazza EC; Myles T; Leung LL
J Thromb Haemost; 2010 May; 8(5):868-76. PubMed ID: 20128866
[TBL] [Abstract][Full Text] [Related]
19. Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice.
Bolliger D; Szlam F; Suzuki N; Matsushita T; Tanaka KA
Thromb Haemost; 2010 Jun; 103(6):1233-8. PubMed ID: 20352163
[TBL] [Abstract][Full Text] [Related]
20. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice.
Nagashima M; Yin ZF; Broze GJ; Morser J
Front Biosci; 2002 Feb; 7():d556-68. PubMed ID: 11815293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
